Literature DB >> 1620142

Kinetic-dynamic relationship of oral levodopa: possible biphasic response after sequential doses in Parkinson's disease.

M Contin1, R Riva, P Martinelli, A Baruzzi.   

Abstract

The potential difference in the concentration-effect relationship of oral sequential doses of levodopa was explored in six Parkinsonian patients with complex fluctuating response. These patients showed "wearing-off phenomena" characterized by a transient worsening of motor function at the end of the first morning dose response to below baseline values and complained of a progressive reduction of levodopa effect during the day. A first standard levodopa dose was given in the morning, after an overnight fast and levodopa withdrawal. A second equal levodopa dose was administered immediately at the end of the first dose deterioration phase. Postimprovement worsening of motor response was also observed after the second levodopa dose in all patients. No significant difference in the pharmacokinetics of levodopa or in duration or magnitude of motor response could be appreciated between the two doses. These results further support the suggestion that, under controlled dietary conditions, plasma levodopa levels and effects relationship is reproducible between doses. Moreover, even when transient deterioration of motor function occurs between levodopa doses, the central dopaminergic system appears to remain responsive to the drug.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1620142     DOI: 10.1002/mds.870070310

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  7 in total

1.  Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-06       Impact factor: 2.745

2.  Disease progression, drug action and Parkinson's disease: why time cannot be ignored.

Authors:  Nick Holford; John G Nutt
Journal:  Eur J Clin Pharmacol       Date:  2007-12-19       Impact factor: 2.953

Review 3.  Pharmacokinetic optimisation in the treatment of Parkinson's disease.

Authors:  M Contin; R Riva; F Albani; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1996-06       Impact factor: 6.447

4.  Effect of low concentrations of apomorphine on parkinsonism in a randomized, placebo-controlled, crossover study.

Authors:  Steven A Gunzler; Caroline Koudelka; Nichole E Carlson; Misha Pavel; John G Nutt
Journal:  Arch Neurol       Date:  2008-02

5.  Dissociable Effects of Serotonin and Dopamine on the Valuation of Harm in Moral Decision Making.

Authors:  Molly J Crockett; Jenifer Z Siegel; Zeb Kurth-Nelson; Olga T Ousdal; Giles Story; Carolyn Frieband; Johanna M Grosse-Rueskamp; Peter Dayan; Raymond J Dolan
Journal:  Curr Biol       Date:  2015-07-02       Impact factor: 10.834

6.  Population pharmacodynamics of IPX066: an oral extended-release capsule formulation of carbidopa-levodopa, and immediate-release carbidopa-levodopa in patients with advanced Parkinson's disease.

Authors:  Zhongping Mao; Ann Hsu; Suneel Gupta; Nishit B Modi
Journal:  J Clin Pharmacol       Date:  2013-02-20       Impact factor: 3.126

7.  Neurochemical Systems of the Retina Involved in the Control of Movement.

Authors:  Gregory L Willis; Christopher B Freelance
Journal:  Front Neurol       Date:  2017-07-05       Impact factor: 4.003

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.